First, there is no hepatitis B immunoglobulin injection for pregnant women in the immunization strategy for hepatitis B recommended by the World Health Organization, and there is no such method in the immunization strategy for hepatitis B recommended by the Ministry of Health in China. Second, the instructions for the use of HBIG do not have the effect of blocking intrauterine transmission of hepatitis B virus, and if its scope of application is expanded, there must be clinical trials and approval by the relevant authorities. Thirdly, in terms of clinical application effects, HBIG given to pregnant women simply cannot block the transmission of hepatitis B virus from pregnant women who are positive for hepatitis B virus surface antigen (HBsAg) to their infants. Most of the papers on intrauterine infection published in China are on the study of artificially induced fetuses, such as induction of labor with rivanol, induction of labor with water bladder, and induction of labor with mifepristone with prostaglandin. Levanol induction of labor can damage fetal liver, kidney, heart, lung and other vital organs, and cause placental tissue degeneration and necrosis; in water bladder induction of labor, placental abruption, detachment degeneration and focal necrosis can occur at the water bladder injection. Therefore, detection of HBVDNA from fetal blood or liver does not necessarily indicate intrauterine infection. In case of intrauterine infection, dynamic changes in HBVDNA and HBV serological markers are seen after the birth of the newborn, and no conclusions can be drawn from the results of one test. When economic conditions allow, instead of giving hepatitis B immunoglobulin to pregnant women, it is better to spend 1/3 of the money to vaccinate newborns of HBsAg-positive mothers. If HBIG is given as early as possible within 24 hours of birth, along with 10 g of recombinant yeast or 20 g of Chinese hamster oocyte (CHO) hepatitis B vaccine, the effectiveness of interrupting mother-to-child transmission can be significantly improved. Alternatively, 1 dose of HBIG can be given within 12 hours of birth, followed by a second dose of HBIG 1 month later, along with a 10g recombinant yeast or 20g CHO hepatitis B vaccine, and a second and third dose of hepatitis B vaccine (10g recombinant yeast or 20g CHO hepatitis B vaccine each) at 1 and 6 months intervals, respectively. The latter is less convenient than the former, but its protection rate is higher than that of the former. Newborns can receive breastfeeding from HBsAg-positive mothers after HBIG and hepatitis B vaccine are administered within 12 hours of birth.